CIBC Private Wealth Group’s Iovance Biotherapeutics IOVA Stock Holding History

CIBC Private Wealth Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-165	Closed	-$284	–	3198
2025 Q2	$284	Buy	+165	New	+$411	﹤0.01%	2884
2024 Q2	–	Sell	-35	Closed	-$497	–	3221
2024 Q1	$497	Buy	+35	New	+$407	﹤0.01%	2936
2018 Q2	–	Sell	-43,000	Closed	-$727K	–	2024
2018 Q1	$727K	Hold	43,000	–	–	﹤0.01%	703
2017 Q4	$344K	Hold	43,000	–	–	﹤0.01%	852
2017 Q3	$333K	Hold	43,000	–	–	﹤0.01%	832
2017 Q2	$316K	Hold	43,000	–	–	﹤0.01%	577
2017 Q1	$320K	Hold	43,000	–	–	﹤0.01%	557
2016 Q4	$299K	Hold	43,000	–	–	﹤0.01%	557
2016 Q3	$354K	Hold	43,000	–	–	﹤0.01%	542
2016 Q2	$348K	Hold	43,000	–	–	﹤0.01%	555
2016 Q1	$218K	Hold	43,000	–	–	﹤0.01%	574
2015 Q4	$332K	Hold	43,000	–	–	﹤0.01%	558
2015 Q3	$248K	Hold	43,000	–	–	﹤0.01%	584
2015 Q2	$394K	Hold	43,000	–	–	﹤0.01%	574
2015 Q1	$521K	Buy	+43,000	New	+$484K	﹤0.01%	543

Other funds holding IOVA

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group's IOVA Position: Q3 2025 in Review

CIBC Private Wealth Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 165 shares — an estimated $284 sold.

CIBC Private Wealth Group first reported a position in IOVA in Q1 2015 and held it in 15 quarters. The position peaked at $727K in Q1 2018. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

CIBC Private Wealth Group reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
CIBC Private Wealth Group sold 165 Iovance Biotherapeutics shares in Q3 2025, an estimated $284.
CIBC Private Wealth Group first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 15 quarters.
CIBC Private Wealth Group's Iovance Biotherapeutics position peaked at $727K in Q1 2018.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on CIBC Private Wealth Group's 13F filing for Q3 2025, filed 24 Nov 2025.